n-acetyllactosamine has been researched along with Pleural Effusion, Malignant in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Carrasco, J; Courtoy, PJ; Demotte, N; Lurquin, C; Moser, M; Schmidt, C; Squifflet, JL; Thielemans, K; van der Bruggen, P; Van Der Smissen, P; Weynand, B; Wieƫrs, G | 1 |
1 other study(ies) available for n-acetyllactosamine and Pleural Effusion, Malignant
Article | Year |
---|---|
A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice.
Topics: Amino Sugars; Animals; Ascites; Breast Neoplasms; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Galectin 3; Humans; Interferon-gamma; Ligands; Lymphocytes, Tumor-Infiltrating; Mastocytoma; Melanoma; Mice; Neoplasms; Pleural Effusion, Malignant; Polysaccharides; Receptors, Antigen, T-Cell | 2010 |